

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Collectar Biosciences, Inc.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

15117F880

(CUSIP Number)

09/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 15117F880

1	Names of Reporting Persons Bleichroeder LP
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 200,000.00
	6	Shared Voting Power 0.00
	7	Sole Dispositive Power 200,000.00
	8	Shared Dispositive Power 0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 200,000.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 6.08 %	
12	Type of Reporting Person (See Instructions) IA	

SCHEDULE 13G

CUSIP No.	15117F880
-----------	-----------

1	Names of Reporting Persons Bleichroeder Holdings LLC	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 200,000.00
	6	Shared Voting Power 0.00
	7	Sole Dispositive Power 200,000.00
	8	Shared Dispositive Power 0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 200,000.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	

11	Percent of class represented by amount in row (9) 6.08 %
12	Type of Reporting Person (See Instructions) HC

SCHEDULE 13G

CUSIP No.	15117F880
-----------	-----------

1	Names of Reporting Persons Andrew Gundlach	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 200,000.00
	6	Shared Voting Power 0.00
	7	Sole Dispositive Power 200,000.00
	8	Shared Dispositive Power 0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 200,000.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 6.08 %	
12	Type of Reporting Person (See Instructions) IN	

SCHEDULE 13G

Item 1.

- (a) Name of issuer:
Celectar Biosciences, Inc.
- (b) Address of issuer's principal executive offices:
100 CAMPUS DRIVE, FLORHAM PARK, NJ 07932

Item 2.

- (a) **Name of person filing:**
[Bleichroeder Holdings LLC](#)
[Bleichroeder LP](#)
[Andrew Gundlach](#)
- (b) **Address or principal business office or, if none, residence:**
[1345 Avenue of the Americas, 47th Floor](#)
[New York, NY 10105](#)
- (c) **Citizenship:**
[Bleichroeder Holdings LLC and Bleichroeder LP: Delaware, USA](#)
[Andrew Gundlach: United States](#)
- (d) **Title of class of securities:**
[Common Shares](#)
- (e) **CUSIP No.:**
[15117F880](#)

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) ☒ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) ☒ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

- (a) **Amount beneficially owned:**
[See cover page.](#)
- (b) **Percent of class:**
[See cover page.](#) %
- (c) **Number of shares as to which the person has:**
- (i) **Sole power to vote or to direct the vote:**
[See cover page.](#)
- (ii) **Shared power to vote or to direct the vote:**
[See cover page.](#)
- (iii) **Sole power to dispose or to direct the disposition of:**
[See cover page.](#)
- (iv) **Shared power to dispose or to direct the disposition of:**

[See cover page.](#)

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

[Bleichroeder LP \("Bleichroeder"\), an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is deemed to be the beneficial owner of 200,000 shares, or 6.08% of the common stock believed to be outstanding as a result of acting as investment adviser to various clients. The 200,000 shares include 100,000 shares of common stock and 100,000 shares of common stock issuable upon exercise of warrants. Clients of Bleichroeder have the right to receive and the ultimate power to direct the receipt of dividends from, or the proceeds of the sale of, such securities.](#)

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

[See Exhibit 99.2](#)

Item 8. Identification and Classification of Members of the Group.

[Not Applicable](#)

Item 9. Notice of Dissolution of Group.

[Not Applicable](#)

Item 10. Certifications:

[By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.](#)

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

[Bleichroeder LP](#)

Signature: [Andrew Gundlach](#)
Name/Title: [President and CEO](#)
Date: [11/14/2025](#)

[Bleichroeder Holdings LLC](#)

Signature: [Andrew Gundlach](#)
Name/Title: [President and CEO](#)
Date: [11/14/2025](#)

[Andrew Gundlach](#)

Signature: [Andrew Gundlach](#)
Name/Title: [Individual](#)
Date: [11/14/2025](#)

AGREEMENT OF THE REPORTING PERSONS

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that such person or entity knows or has reason to believe that such information is inaccurate. This agreement may be executed in any number of counterparts and all of such counterparts taken together shall constitute one and the same instrument.

Date: November 14, 2025

BLEICHROEDER LP

Signature: /s/ [Andrew Gundlach]

Name/Title: Andrew Gundlach, President and CEO

BLEICHROEDER HOLDINGS LLC

Signature: /s/ [Andrew Gundlach]

Name/Title: Andrew Gundlach, President and CEO

ANDREW GUNDLACH

Signature: /s/ [Andrew Gundlach]

Name/Title: Andrew Gundlach, Individual

The identity and the Item 3 classification of the relevant subsidiary is: Bleichroeder LP, which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E).